Events

New Activities

Therapy for Staphylococcus aureus ...

This webinar will review current practices and ongoing controversies in the treatment of Staphylococcus aureus bacteremia, a common infection with ...

Diagnostic and therapeutics in S. ...

This webinar explores the rapidly evolving landscape of Staphylococcus aureus diagnostics and therapeutics, bringing together three complementary perspectives that span ...

Watch

Disinformation in infectious diseases

28 September 2026 A timely ISAC webinar examining how disinformation shapes infectious‑disease communication and public trust.Jon Roozenbeek and ...

Crimean-Congo Haemorrhagic Fever ...

On demand This webinar brings together leading experts to explore the evolving epidemiology, clinical patterns and public health challenges of ...

On demand

Episode 3: Prof. Shaheen Mehtar

In this episode Ian Gould sits down with Professor Shaheen Mehtar (Stellenbosch University, Cape Town; Founding member and Past Chair, ...

Listen

How to get your paper published in IJAA ...

This expert-led webinar, hosted by ISAC and Elsevier, offers practical insights into publishing high quality antimicrobial research.

Watch

Living legends in infectious diseases

Listen to episode 1 of ISAC's new celebrating the individuals whose work has shaped modern infectious diseases, antimicrobial stewardship, diagnostics ...

Listen

4th Polymyxin Conference

Presentations from the 4th International Conference on Polymyxins which ISAC was proud to have endorsed.

Polymyxins in the Era of CROs: Opportunities and Challenges
Co-Chairs: Profs Jian Li and Jing Zhang
8-10 October 2024, Suzhou, China

The conference explored the latest advancements across all major facets of the polymyxin class of antibiotics. Polymyxins are a last-line therapeutic option for treating life threatening infections caused by Gram-negative 'superbugs,' including the WHO priority pathogens Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Day 1
Welcome address	Jian Li / J. Zhang
TREATMENT OF LIFE THREATENING INFECTIONS DUE TO MDR GRAM NEGATIVE BACILLI	David Paterson
Infections Caused by MDR Gram-negative Pathogens: Chinese Perspectives	Minggui Wang
Three different polymyxin products in China: Polymyxin B, colistin and colistin methanesulphonate (CMS)	Jian Li
Clinical Use of Colistin Methanesulfonate (CMS) and Polymyxin B in Critically-ill Patients	Visanu Thamlikitkul
Clinical use of colistin methanesulfonate in patients. Spanish perspectives	Juan-Pablo Horcajada
Clinical Use of Colistin Sulfate in Critically Ill Patients	Baiyi Chen
Clinical use of Polymyxins in critically-ill pediatrics patients	Qing Cao
Nephrotoxicity of Polymyxins in critically-ill patients: risk factors & toxicodynamics	Andrea LH Kwa
Pharmacokinetics of Polymyxins in Different Types of Patients	Gauri Rao
Pharmacokinetics/pharmacodynamics of polymyxins	Cornelia B. Landersdorfer
Selecting the Right Dose of Colistin and Polymyxin B	Visanu Thamlikitkul
The right dose of colistin sulfate: Are we there yet?	Miao Yan
Therapeutic Drug Monitoring of Polymyxins in patients: Spanish perspectives	Sònia Luque
Therapeutic drug monitoring of polymyxins in patients Chinese perspectives	Yaxin Fan
The Most Pressing Needs To Be Studied By Innovative Clinical Trials	Juan-Pablo Horcajada
Overview of Adaptive and Platform Trial Designs	Xiaofang Wang
Innovative Endpoints in Infectious Diseases Clinical Trials	Sean W. X. Ong
The PRACTical Trial Design	David Paterson

Day 2
One Health of polymyxin resistance	Yang Wang
WHAT CAN WE LEARN FROM INHALED COLISTINMETHATSODIUM IN CYSTIC FIBROSIS PATIENTS?	Niels Høiby
Inhaled polymyxins in critically-ill patients	Ilias Karaiskos
Pharmacokinetics/Pharmacodynamics of Inhaled Polymyxins	Yu-Wei Lin
Inhaled Polymyxins: Importance of Formulation and Delivery	Qi (Tony) Zhou
Nebulized polymyxins for VAP: Methodological considerations and lessons from experimental studies	Yinggang Zhu
China Antimicrobial Surveillance Network（CHINET）	Dandan Yin
Polymyxin antimicrobial susceptibility testing & ChiCAST breakpoint	Qiwen Yang
Determination of polymyxin breakpoints underpinned by PK/PD	Xingchen Bian
Difficult-to-treat Gram-negative Infections: Getting the most out of available agents by Diagnostic Combination Platform	Andrea LH Kwa
Combination therapy of polymyxins: PK/PD is the key	Wanzhen Li
Controlled Clinical Studies of Polymyxin Combination	Visanu Thamlikitkul
Clinical evaluation of polymyxin combination therapy against CRO infections	Xiaohua Qin
Antibacterial Drug Discovery and Development Programs and Preclinical and Clinical Services at NIAID	Zuoyu Xu
Development of BRII-693 -- a novel synthetic lipopeptide for top priority MDR pathogens	Yao Zhang
EVER206: Next Generation Polymyxin for the Treatment of Highly Resistant Gram-Negative Bacterial Infections	Sunny Zhu
POLYMYXIN ACTIVITY AGAINST BIOFILM	Niels Høiby
The story of Mcr	Jian-Hua Liu
Epidemiology and evolution of colistin-resistant Enterobacterales	Hui Wang

Day 3
EFFECTS OF POLYMYXIN ON BACTERIAL BIOFILM INFECTIONS: FROM LABORATORY TO CLINIC	Zhijun Song
Inhalation of polymyxins: Efficacy shown within two hours using sputum smears	Xiaoping Huang
EDGE OF ETERNITY	Dongdong Zhao/ Chris Zhao
Present and future of intravenous colistin methanesulfonate in treating pneumonia: The shift towards nebulized colistin methanesulfonate	Luisa Sorlí
Population Pharmacokinetics and Dose Optimization of Polymyxin B in Critically Ill Burn Patients	Jun Yang
Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real-world, retrospective cohort study	Yueliang Xie